ADGM Overview

Adagio Medical Holdings, Inc. is a commercial stage medical device company. It is focused on developing proprietary Ultra-Low Temperature Cryoablation technology that creates contiguous, transmural lesions to treat cardiac arrhythmias, with an emphasis on ventricular tachycardia. It is developing and placing on the European Union (EU) market ablation technologies for the treatment of cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. Its product portfolio consists of three product families: iCLAS atrial ULTC catheter and accessories, vCLAS ventricular ULTC catheter, and Cryopulse atrial PFCA catheter and accessories. All of these catheters share the same ULTC cryoablation console. The iCLAS system is CE-marked with the indication for treatment of paroxysmal atrial fibrillation, persistent atrial fibrillation and atrial flutter. The vCLAS ventricular catheter has been specifically designed for the treatment of ventricular arrhythmia.

Wall Street analysts forecast ADGM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADGM is4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Adagio Medical Holdings Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00

Adagio Medical Holdings Inc. EPS for the last quarter amounts to USD, decreased -100.00

Adagio Medical Holdings Inc (ADGM) has 86 emplpoyees as of March 31 2026.

Today ADGM has the market capitalization of 23.99M USD.